Treatment Factors for Cancer Patients Who Had Interruptions in Radiotherapy Due to Thrombocytopenia and/or Neutropenia, Compared With Controls
| . | Thrombocytopenia Cases (n = 45)3-150 . | Neutropenia Cases (n = 63)3-150 . | Thrombocytopenia . | Controls (n = 138) . |
|---|---|---|---|---|
| . | . | . | + Neutropenia (n = 37)3-150 . | . |
| Patients with previous bone marrow irradiation | 5 (11) | 5 (8) | 5 (14) | 15 (11) |
| Total cumulative percentage of marrow irradiated (score)3-151 | ||||
| <20% 1 | 15 (33) | 23 (37) | 12 (32) | 84 (61) |
| 20-39% 2 | 15 (33)‡ | 22 (35)‡ | 11 (30)‡ | 46 (33) |
| 40-59% 3 | 10 (22)‡ | 11 (18)‡ | 9 (24)‡ | 7 (5) |
| 60-79% 4 | 4 (9)‡ | 6 (10)‡ | 4 (11)‡ | 0 (0) |
| ≥80% 5 | 1 (2)‡ | 1 (2)‡ | 1 (3)‡ | 1 (1) |
| (mean, 31.8) | (mean, 30) | (mean, 34) | (mean, 18) | |
| Patients with concurrent myelosuppressive chemotherapy | 15 (33)‡ | 20 (32)‡ | 12 (32)‡ | 3 (2) |
| Patients with sequential myelosuppressive chemotherapy | 14 (31)ρ | 17 (27)∥ | 14 (38)‡ | 19 (14) |
| Patients with previous myelosuppressive chemotherapy | 20 (44)∥ | 26 (41)∥ | 20 (54)‡ | 35 (25) |
| No. of previous myelosuppressive chemotherapy regimens (score )3-151 | ||||
| 0 0 | 25 (56) | 37 (59) | 17 (46) | 103 (75) |
| 1 1 | 11 (24)ρ | 16 (25)∥ | 11 (30)ρ | 24 (17) |
| 2 2 | 3 (7)ρ | 4 (6)∥ | 3 (8)ρ | 6 (4) |
| ≥3 ≥3 | 6 (13)ρ | 6 (10)∥ | 6 (16)ρ | 5 (4) |
| . | Thrombocytopenia Cases (n = 45)3-150 . | Neutropenia Cases (n = 63)3-150 . | Thrombocytopenia . | Controls (n = 138) . |
|---|---|---|---|---|
| . | . | . | + Neutropenia (n = 37)3-150 . | . |
| Patients with previous bone marrow irradiation | 5 (11) | 5 (8) | 5 (14) | 15 (11) |
| Total cumulative percentage of marrow irradiated (score)3-151 | ||||
| <20% 1 | 15 (33) | 23 (37) | 12 (32) | 84 (61) |
| 20-39% 2 | 15 (33)‡ | 22 (35)‡ | 11 (30)‡ | 46 (33) |
| 40-59% 3 | 10 (22)‡ | 11 (18)‡ | 9 (24)‡ | 7 (5) |
| 60-79% 4 | 4 (9)‡ | 6 (10)‡ | 4 (11)‡ | 0 (0) |
| ≥80% 5 | 1 (2)‡ | 1 (2)‡ | 1 (3)‡ | 1 (1) |
| (mean, 31.8) | (mean, 30) | (mean, 34) | (mean, 18) | |
| Patients with concurrent myelosuppressive chemotherapy | 15 (33)‡ | 20 (32)‡ | 12 (32)‡ | 3 (2) |
| Patients with sequential myelosuppressive chemotherapy | 14 (31)ρ | 17 (27)∥ | 14 (38)‡ | 19 (14) |
| Patients with previous myelosuppressive chemotherapy | 20 (44)∥ | 26 (41)∥ | 20 (54)‡ | 35 (25) |
| No. of previous myelosuppressive chemotherapy regimens (score )3-151 | ||||
| 0 0 | 25 (56) | 37 (59) | 17 (46) | 103 (75) |
| 1 1 | 11 (24)ρ | 16 (25)∥ | 11 (30)ρ | 24 (17) |
| 2 2 | 3 (7)ρ | 4 (6)∥ | 3 (8)ρ | 6 (4) |
| ≥3 ≥3 | 6 (13)ρ | 6 (10)∥ | 6 (16)ρ | 5 (4) |
Because of rounding, percentages, which are in parentheses, do not always add up to 100%.
Comparison of treatment factors for patients who had treatment interruptions due to thrombocytopenia, neutropenia, or both thrombocytopenia and neutropenia when compared with controls yielded P values of ‡ ≤ .001, ρ ≤ .01, and ∥ ≤ .05.
Test based on logistic regression using scores as noted.